Shares of Opthea Limited (NASDAQ:OPT - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 36,145 shares were traded during trading, a decline of 3% from the previous session's volume of 37,414 shares.The stock last traded at $6.03 and had previously closed at $5.33.
Analyst Upgrades and Downgrades
Several research analysts have commented on OPT shares. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Opthea in a research report on Wednesday, January 29th. Canaccord Genuity Group raised Opthea to a "strong-buy" rating in a research note on Tuesday, December 17th.
Get Our Latest Stock Report on OPT
Opthea Stock Performance
The firm's fifty day moving average price is $4.05 and its 200-day moving average price is $3.71.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in OPT. Jane Street Group LLC bought a new position in shares of Opthea in the 3rd quarter worth about $114,000. Twin Lakes Capital Management LLC bought a new stake in Opthea in the third quarter worth approximately $81,000. Finally, ABC Arbitrage SA acquired a new position in Opthea in the fourth quarter valued at approximately $40,000. Institutional investors own 55.95% of the company's stock.
About Opthea
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
See Also
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
